Top
Topic: Drug resistance and cancer stem cell

A special issue of Cancer Drug Resistance.

ISSN 2578-532X (Online)

Submission deadline: 30 Apr 2019

Guest Editor(s)

  • Dr. Miroslav Blumenberg
    The RO Perelman Department of Dermatology, Department of Biochemistry and Molecular Pharmacology, NYU School of Medicine, NY, USA.

    Website | E-mail

Special Issue Introduction

Both solid tumors as well as leukemias and lymphomas depend for their proliferation on a small group of progenitor cells, the cancer stem cells. These are tumorigenic and both self-renew and generate more differentiated, non-tumorigenic cells. The cancer stem cells are responsible for metastases, as well as for the post-therapeutic relapses of tumors. Therefore there is a great interest and importance in identifying and, if possible, specifically targeting the cancer stem cells. Recent developments in single cell omics approaches hold great promise in this regard.
The special issue on “Cancer Stem Cells” will include Original Articles, Reviews and Commentaries, etc. updating the current state of knowledge and clinical uses of identifying and targeting cancer stem cells. The special issue will also include Research articles presenting novel outstanding data on all aspects of cancer stem cell-targeted therapies. All submissions will undergo rigorous peer review and will be published free of charge upon acceptance.

Keywords

Biomarkers, Differentiation therapy, Metastasis, Omics, Relapse, Single cell studies, Stemness.

Submission Deadline

30 Apr 2019

Submission Information

Articles of special issue are free of charge for article processing.
For Author Instructions, please refer to http://cdrjournal.com/pages/view/author_instructions
For Online Submission, please login at http://www.oaemesas.com/cdr
Submission Deadline: 30 Apr 2019
Contacts: Elaine Gao, Managing Editor, editorial@cdrjournal.com
                  Ellie Liang, Editor, ellie.liang@oaepublish.com

Published Articles

This special issue is now open for submission.